Alpha 2.0
Login Register
» Authors » Olivier Veilleux

Olivier Veilleux

Explore the profile of Olivier Veilleux including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 11
Citations 26
Followers 0
Related Specialties
Hematology
Oncology
Top 10 Co-Authors
Jean Roy
Jean-Sebastien Delisle
Imran Ahmad
Sandra Cohen
Guy Sauvageau
Lea Bernard
Thomas Kiss
Denis-Claude Roy
Sylvie Lachance
Nadia Bambace
Published In
Transplant Cell Ther
Blood Adv
CMAJ
Curr Oncol
Hematology
Affiliations
Soon will be listed here.
Recent Articles
1.
Approach to autologous stem cell transplantation in a patient with severe cold agglutinin disease, a case report
Castonguay M, Bernard L, Corriveau M, Castonguay A, Quenneville G, Cohen S, et al.
Transfusion . 2025 Jan; PMID: 39876551
Background: Cold agglutinin disease (CAD) or syndrome (CAS) can be particularly challenging when autologous stem cell transplant (ASCT) is needed. Standard peripheral blood stem cell (PBSC) collection and manipulation involve...
2.
Successful desensitization of donor-specific antibodies in a single cord blood transplant recipient
Tanguay M, Cohen S, Menard I, Meunier M, Delisle J, Roy J, et al.
Hematology . 2025 Jan; 30(1):2448552. PMID: 39763113
Umbilical cord blood (UCB) represents a valuable graft source in the absence of a human leukocyte antigen (HLA)-matched donor for hematopoietic cell transplantation (HCT). Donor-specific anti-HLA antibodies (DSAs), targeting grafts...
3.
A Pilot Study of UM171-Expanded Cord Blood Grafts for Tandem Auto/Allogeneic Hematopoietic Cell Transplant in High and Ultra-High-Risk Myeloma Patients
Roy J, Cohen S, Sauvageau G, Ahmad I, Fournier V, Terra R, et al.
Transplant Cell Ther . 2024 Oct; 31(1):34.e1-34.e14. PMID: 39419177
Multiple myeloma (MM) remains associated with a poor outcome, particularly in patients with advanced disease and high-risk (HR) cytogenetics. To date, the only curative treatment is allogeneic (allo) hematopoietic cell...
4.
Outcomes of adults with refractory or relapsed acute myeloid leukemia treated with azacitidine and venetoclax compared to other therapies: a multicenter retrospective study
Pelland A, Deschenes-Simard X, Savard X, Giguere P, Spillane D, Barabe F, et al.
Leuk Lymphoma . 2024 Aug; 65(13):1974-1982. PMID: 39129334
This study reports characteristics and outcomes of adults who received Azacitidine-Venetoclax (AZA-VEN) compared to other salvage therapies (NO-AZA-VEN) as first salvage therapy for acute myeloid leukemia (AML). The clinical data...
5.
Management of post-autologous transplant relapse in patients with T-cell lymphomas
Veilleux O, Socola F, Arai S, Frank M, Johnston L, Lowsky R, et al.
Am J Hematol . 2024 Apr; 99(8):1485-1491. PMID: 38661220
Autologous hematopoietic cell transplantation (AHCT) is often used as a consolidation for patients with peripheral T-cell lymphomas (PTCLs) due to the poor prognosis associated with this heterogenous group of disorders....
6.
Improved outcomes of UM171-expanded cord blood transplantation compared with other graft sources: real-world evidence
Cohen S, Bambace N, Ahmad I, Roy J, Tang X, Zhang M, et al.
Blood Adv . 2023 Jul; 7(19):5717-5726. PMID: 37467030
Cord blood (CB) transplantation is hampered by low cell dose and high nonrelapse mortality (NRM). A phase 1-2 trial of UM171-expanded CB transplants demonstrated safety and favorable preliminary efficacy. The...
7.
Bortezomib Maintenance After Allogeneic Transplantation in Newly Diagnosed Myeloma Patients Results in Decreased Incidence and Severity of Chronic GVHD
Claveau J, LeBlanc R, Ahmad I, Delisle J, Cohen S, Kiss T, et al.
Transplant Cell Ther . 2022 Nov; 29(1):44.e1-44.e9. PMID: 36334654
Allogeneic hematopoietic cell transplantation (HCT) has curative potential in myeloma but remains hampered by high rates of relapse and chronic graft-versus-host disease (GVHD). We hypothesized that bortezomib (BTZ) as maintenance...
8.
Impact of Implementing a Bendamustine-Based Conditioning Regimen on Outcomes of Autologous Stem Cell Transplantation in Lymphoma while Novel Cellular Therapies Emerge
Lachance S, Bourguignon A, Boisjoly J, Bouchard P, Ahmad I, Bambace N, et al.
Transplant Cell Ther . 2022 Oct; 29(1):34.e1-34.e7. PMID: 36243319
With the advent of new cellular and targeted therapies, treatment options for relapsed and refractory (r/R) lymphomas have multiplied, and the optimal approach offering the best outcomes remains a matter...
9.
Donor Age and Non-Relapse Mortality: Study of Their Association after HLA-Matched Allogeneic Hematopoietic Cell Transplantation for Acute Myeloid Leukemia and Myelodysplastic Syndrome
Kadri Y, Phan M, Bambace N, Bernard L, Cohen S, Delisle J, et al.
Curr Oncol . 2022 Aug; 29(8):5955-5962. PMID: 36005208
The purpose of this retrospective study was to study the correlation between donor age (DA) and non-relapse mortality (NRM) and relapse incidence (RI) among patients treated with allogeneic hematopoietic cell...
10.
Real-World Outcomes of Autologous and Allogeneic Hematopoietic Stem Cell Transplantation for Relapsed/Refractory Hodgkin Lymphoma in the Era of Novel Therapies: A Canadian Perspective
Veilleux O, Claveau J, Alaoui H, Roy J, Ahmad I, Delisle J, et al.
Transplant Cell Ther . 2021 Dec; 28(3):145-151. PMID: 34954149
Despite high cure rates with frontline therapy for Hodgkin lymphoma (HL), approximately 30% of patients will relapse or develop primary refractory disease (R/r). Autologous hematopoietic stem cell transplantation (autoHSCT) is...